ESTRO 2021 Abstract Book

S1021

ESTRO 2021

PO-1236 Stereotactic body radiotherapy in unresectable intrahepatic cholangio-carcinoma: a systematic review S. Bisello 1,2 , F. Bertini 1,2 , G. Tolento 1 , M. Renzulli 3 , F. Medici 1,2 , A. Benini 1,2 , D. Vallerossa 1,2 , G. Macchia 4 , F. Deodato 4,5 , S. Cilla 6 , F. Cellini 5,7 , L. Strigari 8 , A. Angelini 8 , G. Brandi 2,9 , S. Cammelli 1,2 , A.G. Morganti 1,2 , M. Buwenge 1,2 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2 Department of Experimental, Diagnostic, and Specialty Medicine - DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy; 3 Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 4 Radiation Oncology Unit, Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Campobasso, Italy; 5 Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy; 6 Medical Physics Unit, Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Campobasso, Italy; 7 Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Roma, Italy; 8 Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 9 Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Purpose or Objective Among biliary tract cancers, intrahepatic cholangiocarcinoma (ICC) has different characteristics compared to those in other sites. Current guidelines suggest several treatment options including stereotactic radiation therapy (SBRT), chemoradiation and trans-arterial-radio-embolization. However, the role of SBRT in locally advanced ICC is unclear. The aim of this study was to present a systematic review on the efficacy and safety of SBRT in ICC. Materials and Methods A systematic review based on Prisma methodology was performed. Only articles reporting outcome in terms of Overall Survival (OS) after SBRT for unresectable ICC were included. Secondary aim was to report outcomes in terms of Progression Free Survival (PFS), Local Control (LC), and Toxicity. Results Six papers (145 patients) were included in this analysis. SBRT was frequently used as a salvage treatment, since 28.6%-66.7% of patients received previous systemic or local treatments. Median SBRT dose was 45 Gy delivered in 3-5 fractions. With a median follow-up of 16 months, median OS was 14 months (range: 10-48). In a comparison study, SBRT was significantly superior in terms of OS compared to both chemoradiation and trans-arterial-radio-embolization. One-year LC was 85.0% in one study. One–year PFS was 50.0% and 68.0% in two studies, respectively. Toxicity was generally not reported in detail or reported including other sites of biliary cancers. The main outcomes are reported in Table 1. Conclusion Only limited evidence is available on the efficacy of SBRT in ICC. Prospective studies on larger series would be useful. However, based on the available data, SBRT seems to produce similar results compared to other treatments of ICC, with the advantage of being a very short and non-invasive therapy. For these reasons SBRT should be considered in selected ICC patients.

PO-1237 Dose-escalated neoadjuvant chemoradiotherapy for oesophageal or oesophagogastric junction carcinoma V. Duque Santana 1 , F. Lopez-Campos 1 , M. Martin-Martin 1 , L. Pelari Mici 1 , A. Hernandez Corrales 1 , M. Valero Perena 1 , S. Sancho Garcia 1 1 Ramon y Cajal University Hospital, Radiation Oncology, Madrid, Spain

Purpose or Objective Introduction